ALK inhibitor has high response in patients with NSCLC.
McBride
Deborah
D
D030301:Activin Receptors, Type II / Q000037:antagonists & inhibitors* / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; C425364:ACVRL1 protein, human; D030301:Activin Receptors, Type II